.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Updates in CLL: Strategies for Managing Toxicities and Special Patient Considerations

Two experts lead a discussion about chronic lymphocytic leukemia (CLL), focusing on updates in management and special considerations when treating with BTK inhibitors.

EP. 1: Chronic Lymphocytic Leukemia and BTK Inhibitors

February 18th 2022

Amy Goodrich, RN, MSN, CRNP, and Kirollos S. Hanna, PharmD, BCPS, BCOP, provide an overview of chronic lymphocytic leukemia (CLL) and the role BTK inhibitors play in treatment.

EP. 2: Selecting Treatment for CLL and Managing BTK Inhibitor-Associated Toxicities

February 18th 2022

Two experts discuss their approach to selecting therapy for patients with CLL and provide insight on managing adverse events when using BTK inhibitors.

EP. 3: Q and A Session

February 18th 2022

Amy Goodrich, RN, MSN, CRNP, and Kirollos S. Hanna, PharmD, BCPS, BCOP, answer audience questions regarding CLL and BTK inhibitors during a question & answer session.